

2015 Information

Date of announcement	Date of announcement	Statement
2015/01/19	17:20:00	<p>Notice of reducing paid-in capital from withdrawing restricted employee shares and completing official registration.</p> <p>1.Date of the Competent Authority's approval of the capital reduction:2015/01/15</p> <p>2.Date of completion of capital amendment Registration : 2015/01/15</p> <p>3.Effect on the company financial report (including any discrepancy between the amount of paid-in capital and the number of shares outstanding and theeffect on net worth per share):</p> <p>(1)Before withdrawing restricted employee shares:The Company’s paid-in capital was NTD:696,904,950, outstanding shares69,690,495 shares, and Net worth of per share NTD31.27.</p> <p>(2)The withdrawing restricted employee shares were 38,000 shares.</p> <p>(3)After withdrawing restricted employee shares: The Company’s paid-in capital was NTD:696,524,950, outstanding shares 69,652,495 shares, and Net worth of per share NTD31.28.</p> <p>4.Planned share conversion operations:NA</p> <p>5.Estimate listed shares, the ratio of listed shares to outstanding shares, after the capital reduction:NA</p> <p>6.Countermeasures of the aforesaid estimate change in shareholding after the capital reduction:NA</p> <p>7.Any other matters that need to be specified: Net worth of per share was based on 2014.Q3 Financial Statement.</p>
2015/02/12	15:58:59	<p>Notice of independent director’s resignation (The term will be ended on May 31, 2015)</p> <p>1.Date of occurrence of the change:2015/02/12</p> <p>2.Name and resume of the replaced director or supervisor: Walt Cheng,President of DoPont China’s Greater China Electronic Communications Division.</p> <p>3.Name and resume of the replacement: The replacement will be elected at this year’s shareholder’s meeting.</p> <p>4.Type of the change (please enter: “resignation”, “discharge”,“tenure expired” or “new appointment”):Resignation</p> <p>5.Reason for the change:Transferred to China and busy at work.</p> <p>6.Original term of office(from _____ to _____):2013/06/18~2016/06/17</p> <p>7.Effective date of the new appointment:2015/06/12</p> <p>8.Rate of turnover of directors of the same term:14.28%</p> <p>9.Rate of turnover of independent directors of the same term:33.33%</p> <p>10.Any other matters that need to be specified:</p>

		The term will be ended on May 31, 2015.
2015/02/12	15:59:58	<p>Notice of functional committee member's resignation (The term will be ended on May 31, 2015)</p> <p>1.Date of occurrence of the change:2015/02/12</p> <p>2.Name of the functional committees:Audit Committee & Remuneration Committee.</p> <p>3.Name and resume of the replaced member: Walt Cheng, President of DoPont China's Greater China Electronic Communications Division.</p> <p>4.Name and resume of the new member: The replacement will be elected at this year's shareholder's meeting.</p> <p>5.Type of the change (please enter: "resignation", "discharge","tenure expired" or "new appointment"):Resignation</p> <p>6.Reason of the change:Transferred to China and busy at work.</p> <p>7.Original term (from _____ to _____):2013/06/18~2016/06/17</p> <p>8.Effective date of the new member:2015/06/12</p> <p>9.Any other matters that need to be specified:The term will be ended on May 31, 2015</p>
2015/03/13	15:19:10	<p>Donation to related party.</p> <p>1.Date of occurrence of the event:2015/03/13</p> <p>2.The reason for the donation:Support Criminal study</p> <p>3.The total amount of the donation:NTD300,000</p> <p>4.Counterparty to the donation:Criminal Investigation Foundation of R.O.C.</p> <p>5.Relationship to the Company:Related Party</p> <p>6.Name and resume of the independent director that expressed objection or reservation:NA</p> <p>7.Contents of the objection or reservation:NA</p> <p>8.Any other matters that need to be specified:NA</p>
2015/03/13	15:19:26	<p>Convnetion of 2015 general shareholders' meeting.</p> <p>1.Date of the board of directors resolution:2015/03/13</p> <p>2.Date for convening the shareholders' meeting:2015/06/12</p> <p>3.Location for convening the shareholders' meeting: 186-2, Hai-Hu-Tsun, Lu-Chu-Hsiang, Taoyuan, Taiwan(Premises of SCI Pharmtech, Inc.)</p> <p>4.Cause or subjects for convening the meeting:</p> <p>1. Report Subjects:</p> <p>(1)Report on operating results of 2014</p> <p>(2)Report by Audit Committee on auditing of 2014 financial statements</p>

		<p>(3)Report on donation to related party</p> <p>(4)Amendment to Code of Ethical Business Management</p> <p>(5)Amendment to Code of Ethics</p> <p>(6)Enactment of Procedure Governing Corporate Social Responsibility</p> <p>2. Recognition subjects:</p> <p>(1)Recognition of 2014 operation report and financial statements</p> <p>(2)Distribution of retained earnings</p> <p>3. Approval and election subjects:</p> <p>(1)Amendment to Article of Incorporation</p> <p>(2)Amendment to Procedure governing the election of directors</p> <p>(3)Election of independent director</p> <p>(4)Lifting ban on independent director from running the same business as SCI</p> <p>5.Book closure starting date:2015/04/14</p> <p>6.Book closure ending date:2015/06/12</p> <p>7.Any other matters that need to be specified:NA</p>
2015/03/13	15:19:40	<p>The Board proposed earnings distribution.</p> <p>1.Date of the board of directors resolution :2015/03/13</p> <p>2.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):3.30</p> <p>3.Cash distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0</p> <p>4.Total amount of cash distributed to shareholders (NT\$):228,883,034</p> <p>5.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):0</p> <p>6.Stock distributed from legal reserve and capital surplus to shareholders (NT\$ per share):0</p> <p>7.Total amount of stock distributed to shareholders (shares):0</p> <p>8.Remunerations for directors and supervisors (NT\$):4,767,110</p> <p>9.Cash bonus to employees (NT\$):32,751,804</p> <p>10.Stock bonus to employees (NT\$):0</p> <p>11.Any other matters that need to be specified:NA</p>
2015/03/16	10:12:42	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2015/03/17</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:15F., No 101, Songren Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website:</p>

		<p>http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified:NA</p>
2015/04/24	11:11:55	<p>Clarification on media reporting.</p> <p>1.Date of occurrence of the event:2015/04/24</p> <p>2.Company name:SCI Pharmtech, Inc.</p> <p>3.Relationship to the Company (please enter " head office" or " subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:Not applicable</p> <p>5.Name of the reporting media:Business Times B1 Layout</p> <p>6.Content of the report:2015 EPS has the potential to reach 5/share.</p> <p>7.Cause of occurrence:</p> <p>The report is simply a forecast made by outsiders. SCI hasn't disclosed to the public 2015 financial forecast and, therefore, all information should be based on and referred to what has been disclosed on the Market Observation Post System.</p> <p>8.Countermeasures:Issued the critical notice to make a clarification.</p> <p>9.Any other matters that need to be specified:</p> <p>2015 Q1 unaudited pretax income of SCI was NT\$113,667 thousand.</p> <p>For details,please refer to M.O.P.S..</p>
2015/05/13	14:41:41	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2015/05/15</p> <p>2.Time of the investor conference:14:00</p> <p>3.Location of the investor conference:7F., No 22, Sec. 1, Chang'an E. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference:</p> <p>Brief recent operating results</p> <p>5.The presentation of the investor conference release:</p> <p>http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company's website:</p> <p>http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified:NA</p>
2015/06/12	15:50:02	<p>Notice of the resolutions of 2015 general shareholders' meeting.</p> <p>1.Date of the shareholders' meeting:2015/06/12</p> <p>2.Important resolutions:</p> <p>(1)Approved the operation report and financial statements of 2014.</p> <p>38,321,628 shares represented by shareholders present in person or by proxy.</p> <p>(including 789,089 shares casted electronically) approval votes : 38,003,521 votes</p>

(including 470,982 votes casted electronically); 99.17% of the total represented at the time of voting. disapproval votes : 1,148 votes(including 1,148 votes casted electronically); invalid votes: 0 votes; abstention votes/no votes : 316,959 votes(including 316,959 votes casted electronically), Approved by more than one half of the voting rights exercised by the shareholders representing a majority of the outstanding shares.

(2)Approved the distribution of retained earnings.

38,321,628 shares represented by shareholders present in person or by proxy. (including 789,089 shares casted electronically) approval votes : 38,003,519 votes (including 470,980 votes casted electronically); 99.17% of the total represented at the time of voting. disapproval votes : 1,150 votes(including 1,150 votes casted electronically); invalid votes: 0 votes;abstention votes/no votes : 316,959 votes(including 316,959 votes casted electronically), Approved by more than one half of the voting rights exercised by the shareholders representing a majority of the outstanding shares.

(3)Approved the amendment to Article of Incorporation.

38,321,628 shares represented by shareholders present in person or by proxy. (including 789,089 shares casted electronically)approval votes : 38,003,312 votes (including 470,773 votes casted electronically); 99.17% of the total represented at the time of voting. disapproval votes : 1,147 votes(including 1,147 votes casted electronically); invalid votes: 0 votes; abstention votes/no votes : 317,169 votes(including 317,169 votes casted electronically),
Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.

(4)Approved the amendment to Procedure governing the election of directors.

38,321,628 shares represented by shareholders present in person or by proxy. (including 789,089 shares casted electronically) approval votes : 38,003,308 votes (including 470,769 votes casted electronically); 99.17% of the total represented at the time of voting. disapproval votes : 1,151 votes(including 1,151 votes casted electronically); invalid votes: 0 votes; abstention votes/no votes : 317,169 votes(including 317,169 votes casted electronically), Approved by more than one half of the voting rights exercised by the shareholders representing a majority of the outstanding shares.

(5)New appointment the director.

Elected as below:

Title	Name	Votes
Independent Director	Chia-Chun Jay Chen	37,996,737 V

(6)Approved the lifting ban on independent director from running the same business as SCI.

38,321,628 shares represented by shareholders present in person or by proxy. (including 789,089 shares casted electronically) approval votes : 37,660,849 votes

		<p>(including 128,310 votes casted electronically); 98.28% of the total represented at the time of voting. disapproval votes : 343,509 votes(including 343,509 votes casted electronically); invalid votes: 0 votes; abstention votes/no votes : 317,270 votes(including 317,270 votes casted electronically), Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.</p> <p>3.Endorsement of the annual financial statements (indicate “yes” or “no”): Yes</p> <p>4.Any other matters that need to be specified: NA</p>
2015/06/12	15:50:15	<p>Notice of independent director’ s new appointment.</p> <p>1.Date of occurrence of the change:2015/06/12</p> <p>2.Name and resume of the replaced director or supervisor:NA</p> <p>3.Name and resume of the replacement: Professor Chia-Chun Jay Chen, Department of Chemistry, National Taiwan Normal University.</p> <p>4.Type of the change (please enter: “resignation” , “discharge” , “tenure expired” or “new appointment”):new appointment</p> <p>5.Reason for the change: Election of independent director at Shareholders' Meeting</p> <p>6.Original term of office(from_____to_____):2013/06/18~2016/06/17</p> <p>7.Effective date of the new appointment:2015/06/12</p> <p>8.Rate of turnover of directors of the same term:14.28%</p> <p>9.Rate of turnover of independent directors of the same term:33.33%</p> <p>10.Any other matters that need to be specified:None</p>
2015/06/12	15:50:28	<p>Notice of Lifting ban on independent director from running the same business as SCI.</p> <p>1.Date of the shareholders' meeting resolution:2015/06/12</p> <p>2.Name and title of the director with permission to engage in competitive conduct: Director, Professor Chia-Chun Jay Chen, Department of Chemistry, National Taiwan Normal University.</p> <p>3.Items of competitive conduct in which the director is permitted to engage: Companies running the same or similar businesses with SCI.</p> <p>4.Period of permission to engage in the competitive conduct: During the term of the Director.</p> <p>5.Circumstances of the resolution (please describe the results of the voting under Article 209 of the Company Act): Approved by more than two thirds of the voting rights exercised by the shareholders representing a majority of the outstanding shares.</p> <p>6.If the permitted competitive conduct is business of a mainland China area enterprise, the name and title of the director (if it is not business of a mainland China area enterprise, please enter ” not applicable” below): NA</p>

		<p>7. Company name of the mainland China area enterprise and the director's position in the enterprise: NA</p> <p>8. Address of the mainland China area enterprise: NA</p> <p>9. Business items of the mainland China area enterprise: NA</p> <p>10. Degree of effect on the Company's finances and business: NA</p> <p>11. If the director has invested in the mainland China area enterprise, the monetary amount of the director's investment and the director's shareholding ratio: NA</p> <p>12. Any other matters that need to be specified: NA</p>
2015/06/12	15:50:42	<p>Notice of functional committee member's change.</p> <p>1. Date of occurrence of the change: 2015/06/12</p> <p>2. Name of the functional committees: Audit Committee & Remuneration Committee.</p> <p>3. Name and resume of the replaced member: NA</p> <p>4. Name and resume of the new member: Professor Chia-Chun Jay Chen, Department of Chemistry, National Taiwan Normal University.</p> <p>5. Type of the change (please enter: "resignation", "discharge", "tenure expired" or "new appointment"): new appointment</p> <p>6. Reason of the change: Election of independent director at Shareholders' Meeting.</p> <p>7. Original term (from _____ to _____): 2013/06/18~ 2016/06/17</p> <p>8. Effective date of the new member: 2015/06/12</p> <p>9. Any other matters that need to be specified: None</p>
2015/06/30	18:01:32	<p>Notice of the record date for common share dividend.</p> <p>1. Date of the resolution by the board of directors or shareholders' meeting or decision by the Company: 2015/06/30</p> <p>2. Type of ex-rights or ex-dividend (please enter: "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"): Ex-dividend</p> <p>3. Type and monetary amount of dividend distribution: Cash dividends of NT\$228,883,034</p> <p>4. Ex-rights (ex-dividend) trading date: 2015/07/28</p> <p>5. Last date before book closure: 2015/07/29</p> <p>6. Book closure starting date: 2015/07/30</p> <p>7. Book closure ending date: 2015/08/03</p> <p>8. Ex-rights (ex-dividend) record date: 2015/08/03</p> <p>9. Any other matters that need to be specified: The payment date of the cash distribution is August 18, 2015.</p>

2015/06/30	18:01:44	<p>The Board of Directors approved retrieval of restricted employee shares.</p> <ol style="list-style-type: none"> 1.Date of the board of directors resolution:2015/06/30 2.Reason for the capital reduction: Some employees resigned, the Board of Directors, accordingly, resolved to retrieve the restricted employee shares. 3.Amount of the capital reduction:NT\$180,000 4.Cancelled shares:18,000 shares 5.Capital reduction ratio:0.025% 6.Share capital after the capital reduction:NT\$732,981,200 (the share capital includes 3,663,625 common shares which were converted from CB and are still unregistered) 7.Scheduled date of the shareholders' meeting:NA 8.Estimate listed shares, the ratio of listed shares to outstanding shares, after the capital reduction:NA 9.Countermeasures of the aforesaid estimate change in shareholding after the capital reduction:NA 10.Any other matters that need to be specified: The record date of capital reduction on 2015/06/26.
2015/06/30	18:01:51	<p>Donation to related party.</p> <ol style="list-style-type: none"> 1.Date of occurrence of the event:2015/06/30 2.The reason for the donation:Promote domestic sports culture 3.The total amount of the donation:NT\$1,500,000 4.Counterparty to the donation:Foundation for Taiwan Masters Golf Tournament 5.Relationship to the Company:Related Party 6.Name and resume of the independent director that expressed objection or reservation:NA 7.Contents of the objection or reservation:NA 8.Any other matters that need to be specified:NA
2015/07/09	16:00:34	<p>Adjustment of cash dividend</p> <ol style="list-style-type: none"> 1.Date of the resolution by the board of directors or shareholders' meeting or decision by the Company:2015/07/09 2.Type of ex-rights or ex-dividend (please enter: "Ex-rights" ," Ex-dividend" , or " Ex-rights and dividend"):Ex-dividend 3.Type and monetary amount of dividend distribution: Cash dividends of NT\$228,883,034 (NTD3.11137144 per common share) 4.Ex-rights (ex-dividend) trading date:2015/07/28 5.Last date before book closure:2015/07/29 6.Book closure starting date:2015/07/30 7.Book closure ending date:2015/08/03 8.Ex-rights (ex-dividend) record date:2015/08/03

		<p>9. Any other matters that need to be specified:</p> <p>(1) The payment date of the cash distribution is August 18, 2015.</p> <p>(2) The capital has increased by 4,204,896 common shares converted from CB, so cash dividend is adjusted, accordingly.</p>
2015/07/22	14:04:28	<p>Invited to brief recent operating results</p> <p>1. Date of the investor conference: 2015/07/24</p> <p>2. Time of the investor conference: 14:30</p> <p>3. Location of the investor conference: No. 700, MingShui Rd., Taipei City</p> <p>4. Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5. The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6. Will the presentation be released in the Company's website: http://www.sci-pharmtech.com.tw</p> <p>7. Any other matters that need to be specified: NA</p>
2015/08/21	15:13:48	<p>Notice of reduction paid-in capital from withdrawing restricted employee shares and completion official registration.</p> <p>1. Date of the Competent Authority's approval of the capital reduction: 2015/08/21</p> <p>2. Date of completion of capital amendment registration: 2015/08/21</p> <p>3. Effect on the company financial report (including any discrepancy between the amount of paid-in capital and the number of shares outstanding and the effect on net worth per share):</p> <p>(1) Before withdrawing restricted employee shares: The Company's paid-in capital was NTD:696,524,950, outstanding shares 69,652,495 shares, and Net worth of per share NTD35.07</p> <p>(2) The withdrawing restricted employee shares were 18,000 shares.</p> <p>(3) After withdrawing restricted employee shares: The Company's paid-in capital was NTD:732,981,200, outstanding shares 73,298,120 shares (the paid-in capital includes 3,663,625 common shares which were converted from CB and were registered), and Net worth of per share NTD33.32</p> <p>4. Planned share conversion operations: NA</p> <p>5. Estimate listed shares, the ratio of listed shares to outstanding shares, after the capital reduction: NA</p> <p>6. Countermeasures of the aforesaid estimate change in shareholding after the capital reduction: NA</p> <p>7. Any other matters that need to be specified: Net worth of per share was based on 2015.Q2 Financial Statement.</p>

2015/09/09	16:34:28	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2015/09/11</p> <p>2.Time of the investor conference:14:30</p> <p>3.Location of the investor conference:11F, No. 97, Sec. 2, Dunhua S. Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference:Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company' s website: http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified:NA</p>														
2015/11/10	18:02:00	<p>The change of increase cash capital plan and the 1st domestic unsecured convertible bonds in 2013.</p> <p>1.Date of the board of directors resolution for the change:2015/11/10</p> <p>2.Dates of effective registration of the original plan:2013/7/10</p> <p>3.Reason for the change: Due to overseas and domestic competitors subsequently investing in the development and manufacturing of high-potent and sterile APIs and formulation, there are concerns that this specific market would get overly competitive and increasingly risky. Furthermore, in consideration of SCI' s current strong growth, it will be a more sensible decision that the resources are poured into the existing businesses instead of subsidiary investment.</p> <p>4.Content of each and every successive past changed plan for raising of funds before and after change: (1)Original plan (Unit : in thousand of NT\$)</p> <table data-bbox="603 1350 986 1480"> <tr> <td>Bank loan payment</td> <td>580,000</td> </tr> <tr> <td>Subsidiary investment</td> <td>716,000</td> </tr> <tr> <td>Total</td> <td>1,296,000</td> </tr> </table> <p>(2)modified plan (unit : in thousand of NT\$)</p> <table data-bbox="603 1543 991 1720"> <tr> <td>Bank loan payment</td> <td>580,000</td> </tr> <tr> <td>Subsidiary investment</td> <td>220,104</td> </tr> <tr> <td>Operating fund</td> <td>495,896</td> </tr> <tr> <td>Total</td> <td>1,296,000</td> </tr> </table> <p>5.Anticipated timetable for execution: Bank loan payment : already implemented in the third quarter of 2013. Subsidiary investment : already implemented in the third quarter of 2015. Operating fund : scheduled to be completed in the fourth quarter of 2015.</p> <p>6.Anticipated completion date: Operating fund : scheduled to be completed in the fourth quarter of 2015.</p> <p>7.Anticipated possible benefits: The fund to be retained can be utilized for flexible employments in the</p>	Bank loan payment	580,000	Subsidiary investment	716,000	Total	1,296,000	Bank loan payment	580,000	Subsidiary investment	220,104	Operating fund	495,896	Total	1,296,000
Bank loan payment	580,000															
Subsidiary investment	716,000															
Total	1,296,000															
Bank loan payment	580,000															
Subsidiary investment	220,104															
Operating fund	495,896															
Total	1,296,000															

		<p>future in an attempt to enhance operational flexibility in business expansion, save interest expense, reduce the dependence on banks and eliminate financial risk.</p> <p>8.Difference with original anticipated benefits: The difference is the originally projected investment income stemming from the subsidiary, which is 363.5 million, 1,068 million, 984.6 million and 1,013.4 million from 2018-2021, respectively.</p> <p>9.Effect of the current change on shareholder equity: The project amendment can keep the flexibility of fund employment for investing in future expansion and reducing operational risks, so there are supposed to be no negative impacts.</p> <p>10.Abstract of the original lead underwriter' s appraisal opinion: SCI' s 2nd quarter revenues were 579,644 thousand, a historical high, growing by 39.19 percent from the year earlier. As of September, 2015, the cumulative revenues also saw a growth of 26.14 percent compared to last year' s, which takes on significant momentum arising from its market demand and requires more resources invested to deal with future orders. In addition, the benefit of subsidiary investment using the remaining fund of 495,896 thousand raised in 2013 are uncertain in consideration of market situation. Judging from SCI' s current business, industry development, future orders, capacity utilization, etc, it is necessary and reasonable to make an amendment to reduce the investment in subsidiary. As to enriching operating capital, over the first two quarters in 2014 and 2015, SCI' s raw material purchases increased from 325,310 thousand to 375,803 thousand while operating expenses hiked from 101,386 thousand to 118,064 thousand, respectively, which indicates that SCI is in need of operating capital for raw material procurement, R&D and other daily operational affairs. Moreover, SCI accordingly has to inject more capital expenditure in keeping with market growth. Therefore, enriching operating capital is achievable and sensible.</p> <p>11.Any other matters that need to be specified:None</p>
2015/12/01	15:23:23	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2015/12/03</p> <p>2.Time of the investor conference:14:00</p> <p>3.Location of the investor conference:13F, No. 200, Keelung Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference: Brief recent operating results</p> <p>5.The presentation of the investor conference release: http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company' s website:</p>

		<p>http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified:NA</p>
2015/12/11	15:03:41	<p>Invited to brief recent operating results</p> <p>1.Date of the investor conference:2015/12/15</p> <p>2.Time of the investor conference:14:00</p> <p>3.Location of the investor conference:No. 700, Mingshui Rd., Taipei City</p> <p>4.Brief information disclosed in the investor conference:</p> <p style="padding-left: 2em;">Brief recent operating results</p> <p>5.The presentation of the investor conference release:</p> <p style="padding-left: 2em;">http://webpro2.twse.com.tw/WebPortal/</p> <p>6.Will the presentation be released in the Company' s website:</p> <p style="padding-left: 2em;">http://www.sci-pharmtech.com.tw</p> <p>7.Any other matters that need to be specified:NA</p>